About Us
StromaGenesis, Inc. is a molecular diagnostics company developing proprietary tests designed to improve cancer patient outcomes. Founded by Dr. Richard Pestell, MD, PhD, MBA, the company’s technology is built on 18 years of academic research and $10 million in public grant funding, resulting in over 36 peer-reviewed publications and validated diagnostic models across 480+ patient samples.
Headquartered in Wynnewood, Pennsylvania, StromaGenesis is now transitioning from R&D to commercialization. The current $15 million Series A round will fund:
CLIA Lab Certification
U.S. and E.U. Commercial Rollout
Regulatory Filings, and Working Capital
This round precedes a planned NASDAQ uplisting, positioning StromaGenesis for broad-scale market entry in precision oncology.
Dr. Richard G. Pestell, AO, is an internationally recognized leader in oncology, endocrinology, and cancer research. His career spans prominent academic and clinical positions, including major leadership roles at Georgetown University Medical Center and Thomas Jefferson University. Dr. Pestell brings the rare combination of deep scientific expertise and proven entrepreneurial execution needed to successfully advance the company’s mission and commercial strategy.
As of the Valuation Date, the Company’s platform had been scientifically validated; and as a result of this progress, the Company estimates a short commercialization runway of approximately 24 months, pending completion of regulatory milestones and strategic partnerships.
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
General inquiries:
© 2025 StromaGenesis. All rights reserved.
Privacy Policy